UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $100.43 and last traded at $100.18, with a volume of 7440 shares. The stock had previously closed at $98.57.
UCB Stock Up 1.6 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average price is $96.52 and its 200 day moving average price is $89.85.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Where to Find Earnings Call Transcripts
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- How to Plot Fibonacci Price Inflection Levels
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
